ALPHARETTA, Ga., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that it received notification from the U.S. Food and Drug Administration (FDA) that the Agency has accepted for review the New Drug Application (NDA) for XIPERE (triamcinolone acetonide ophthalmic suspension) for Suprachoroidal Injection for the treatment of macular edema associated with uveitis. The FDA has determined that the application is sufficiently complete to permit a substantive review.


It may seem like the scene from a sci-fi movie, but future conflicts could be fought using killer robots, with artificial intelligence giving robots free reign. For this reason, a new campaign is calling for a global ban on developing such machines.
At the conceptual level the idea of killer robots is no longer a remote possibility. Already drones and other military machines can be piloted remotely, and some are equipped with missiles. Given the pace of development in relation of autonomous technology for vehicles, and the advances with artificial intelligence in general, the idea of a machine that can directs itself in battle is plausible and, some might argue, inevitable.

SAO PAULO/RIO DE JANEIRO (Reuters) - Brazilian police arrested eight employees of mining firm Vale SA on Friday, accused by state prosecutors of covering up weaknesses at a dam that collapsed and likely killed more than 300 people.

Aphria Inc. (NYSE: APHA) today announced that its Board of Directors (the "Board") has accepted and considered the report of the special committee of independent directors (the "Special Committee"), which reviewed the allegations made against the Company in respect of the Company's previously completed acquisition of LATAM Holdings Inc. (the "Acquisition").

Special Committee Review of LATAM Assets

In accordance with its mandate announced on December 6, 2018, the Special Committee completed its review of the Acquisition with the assistance of independent legal advisor Lenczner Slaght Royce Smith Griffin LLP, independent forensic advisors Deloitte LLP and independent financial advisors Duff & Phelps Canada Limited. The Special Committee's work included a review of the Company's books and records and other documents, meetings with certain financial and legal advisors to the Company and, where available, certain members of senior management and directors of the Board.

Veru (NASDAQ:VERU) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.04) by 25 percent. This is a 62.5 percent increase over losses of $(0.08) per share from the same period last year.

Mike Pompeo arrives in Poland to discuss the Middle East. The US secretary of state will give a keynote address at the security event. Several key diplomats have declined to attend, amid a widening rift (paywall) between the US and its traditional EU partners over Iran.